PDSi engineers have developed the world’s first mobile PET/CT scanner using the most modern technologies in molecular imaging to create a high-performance imager with a small footprint.


This system will create the best clinically available PET/CT images of the brain.

The system can be sited in a standard hospital room, runs from regular office power, and does not require special cooling or shielding.  This is in contrast to the site preparations for a traditional PET/CT that can cost in excess of a million dollars.

The system is designed to create images with two (2)mm spatial resolution, which is a factor of two better than currently available clinical systems. The sensitivity is more than a factor of two greater than presently available clinical system.

Since the system can be readily moved from one area to another using an internal electric drive, it can be used in a variety of environments including intensive care units, surgical suites, neurologist offices, assisted living facilities, and even mobile installation in trucks.  The system is also appropriate for traditional uses of PET/CT in neuro-oncology.  Some collaborative partners are using it for innovative applications such as proton-therapy dosimetry.ems.  This combination allows it to detect much smaller concentrations of molecular imaging compounds, and can lead to a reduction in the radiation dose to the patient and the operator.


PDSi is currently working in collaboration with doctors at Massachusetts General Hospital, University of Pittsburgh Medical Center, and other leaders in molecular imaging to validate the system in a clinical research setting.

The machine is now available for human clinical research, and pre-clinical research on animals.

In addition to the neurological applications, researchers have identified applications such as tuberculosis investigations in primate models, proton therapy dosimetry in cancer patients, and interoperative imaging. These early research customers will allow PDSi to optimize both the machine and its applications while the clinical neuro-scanning application develops.

*** This device is available for research use only until pre-market clearance from the FDA. ***